Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention

被引:97
作者
Kismet, K
Akay, MT [1 ]
Abbasoglu, O
Ercan, A
机构
[1] Hacettepe Univ, Fac Sci, Dept Biol, TR-06532 Ankara, Turkey
[2] Ankara Res & Training Hosp, Gen Surg Dept 4th, Ankara, Turkey
[3] Hacettepe Univ, Sch Med, Dept Surg, TR-06100 Ankara, Turkey
[4] Hacettepe Univ, Beytepe Med Ctr, TR-06100 Ankara, Turkey
来源
CANCER DETECTION AND PREVENTION | 2004年 / 28卷 / 02期
关键词
celecoxib; non-steroidal anti-inflammatory drugs; cyclooxygenase; chemoprevention;
D O I
10.1016/j.cdp.2003.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-steroidal anti-inflaminatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Selective COX-2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. For this purpose, celecoxib is being used for different cancer types. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention. (C) 2004 Published by Elsevier Ltd. on behalf of International Society for Preventive Oncology.
引用
收藏
页码:127 / 142
页数:16
相关论文
共 173 条
[1]   Colon cancer prevention by NSAIDs: What is the mechanism of action? [J].
Ahnen, DJ .
EUROPEAN JOURNAL OF SURGERY, 1998, 164 :111-114
[2]  
Alshafie GA, 2000, ONCOL REP, V7, P1377
[3]  
Alshafie GA, 1999, ANTICANCER RES, V19, P1
[4]   Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].
Altorki, NK ;
Keresztes, RS ;
Port, JL ;
Libby, MD ;
Korst, RJ ;
Flieder, DB ;
Ferrara, CA ;
Yankelevitz, DF ;
Subbaramaiah, K ;
Pasmantier, MW ;
Dannenberg, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650
[5]  
*AM CANC SOC INC, 2003, AM CANC SOC STAT BRE
[6]  
*AM CANC SOC INC, 2003, AM CANC SOC STAT PRO
[7]  
*AM CANC SOC INC, 2003, AM CANC SOC STAT COL
[8]  
*AM CANC SOC INC, 2003, AM CANC SOC STAT CAN
[9]   Inhibition of solar simulator-induced p53 mutations and protection against skin cancer development in mice by sunscreens [J].
Ananthaswamy, HN ;
Ullrich, SE ;
Mascotto, RE ;
Fourtanier, A ;
Loughlin, SM ;
Khaskina, P ;
Bucana, CD ;
Kripke, ML .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (05) :763-768
[10]   Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line [J].
Arico, S ;
Pattingre, S ;
Bauvy, C ;
Gane, P ;
Barbat, A ;
Codogno, P ;
Ogier-Denis, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (31) :27613-27621